The Effect of Potato Protease Inhibitor II on Gastrointestinal Hormones and Satiety in Humans During Weight Reduction

Marion Flechtner-Mors, 1 Ulrike Thoma, 2 Regina Wittmann, 2 Bernhard O Boehm, 2–4 Mona Mors, 1 Jürgen M Steinacker, 1 Uwe Schumann 1 1University Medical Center Ulm, Division of Sports and Rehabilitation Medicine, University Hospital Ulm, Ulm, Germany; 2Department of Internal Med...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Flechtner-Mors M, Thoma U, Wittmann R, Boehm BO, Mors M, Steinacker JM, Schumann U
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
Acceso en línea:https://doaj.org/article/40a089c1b79d4c979d2fc93d97097cd4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:40a089c1b79d4c979d2fc93d97097cd4
record_format dspace
spelling oai:doaj.org-article:40a089c1b79d4c979d2fc93d97097cd42021-12-02T06:47:48ZThe Effect of Potato Protease Inhibitor II on Gastrointestinal Hormones and Satiety in Humans During Weight Reduction1178-7007https://doaj.org/article/40a089c1b79d4c979d2fc93d97097cd42020-02-01T00:00:00Zhttps://www.dovepress.com/the-effect-of-potato-protease-inhibitor-ii-on-gastrointestinal-hormone-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Marion Flechtner-Mors, 1 Ulrike Thoma, 2 Regina Wittmann, 2 Bernhard O Boehm, 2–4 Mona Mors, 1 Jürgen M Steinacker, 1 Uwe Schumann 1 1University Medical Center Ulm, Division of Sports and Rehabilitation Medicine, University Hospital Ulm, Ulm, Germany; 2Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany; 3Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore; 4Imperial College London, London, UKCorrespondence: Marion Flechtner-MorsDepartment of Internal Medicine II, Division of Sports and Rehabilitation Medicine, University Hospital Ulm, Leimgrubenweg 14, Ulm 89075, GermanyTel + 49 731 50045330Fax + 49 731 50045333Email marion.flechtner-mors@uni-ulm.deContext: It is questioned whether the potato protein protease inhibitor II (PI2) reduces appetite and exerts effects on the satiety hormone cholecystokinin (CCK).Objective: To investigate PI2 impact on gastrointestinal hormones and appetite measures during weight reduction.Design: In a randomized, placebo-controlled trial over 20 weeks, fifty-two overweight/obese participants (BMI 25.2– 38.0 kg/m 2) received a protein-rich diet (30%) adjusted to 500 kcal below their individual daily needs. Subjects ingested a capsule containing either PI2 (150 mg) or placebo twice daily 1 hr before lunch and dinner. At week 0 and week 10 participants joined breakfast test meals to determine CCK, GLP-1, ghrelin, leptin, glucose and insulin concentrations in a time course experimental manner. Appetite sensations were measured on test meal days and in week 4, 9, 14 and 19 using visual analogue scales.Results: Weight loss at week 10 and 20 in the PI2 group was 4.3± 3.1 kg and 5.6± 4.1 kg, in the control group: 4.7± 4.0 kg and 6.8± 3.7 kg. A significant effect of PI2 on circulating CCK levels was observed at week 10. The other hormones were unaffected by PI2. At week 10, PI2 group subjects showed higher satiety and decreased desire to eat compared to placebo. During study duration, PI2 showed a significant impact on appetite ratings prior to lunch, one hour before dinner and just before dinner.Conclusion: PI2 increased circulating CCK plasma levels during the diet intervention. Likewise, PI2 modulated appetite sensation from week 4 to 20. The study demonstrated that the PI2 can modulate a key satiety signal.Keywords: dietary supplement, appetite, satiety modification, obesityFlechtner-Mors MThoma UWittmann RBoehm BOMors MSteinacker JMSchumann UDove Medical Pressarticledietary supplementappetitesatiety modificationobesitySpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 521-534 (2020)
institution DOAJ
collection DOAJ
language EN
topic dietary supplement
appetite
satiety modification
obesity
Specialties of internal medicine
RC581-951
spellingShingle dietary supplement
appetite
satiety modification
obesity
Specialties of internal medicine
RC581-951
Flechtner-Mors M
Thoma U
Wittmann R
Boehm BO
Mors M
Steinacker JM
Schumann U
The Effect of Potato Protease Inhibitor II on Gastrointestinal Hormones and Satiety in Humans During Weight Reduction
description Marion Flechtner-Mors, 1 Ulrike Thoma, 2 Regina Wittmann, 2 Bernhard O Boehm, 2–4 Mona Mors, 1 Jürgen M Steinacker, 1 Uwe Schumann 1 1University Medical Center Ulm, Division of Sports and Rehabilitation Medicine, University Hospital Ulm, Ulm, Germany; 2Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany; 3Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore; 4Imperial College London, London, UKCorrespondence: Marion Flechtner-MorsDepartment of Internal Medicine II, Division of Sports and Rehabilitation Medicine, University Hospital Ulm, Leimgrubenweg 14, Ulm 89075, GermanyTel + 49 731 50045330Fax + 49 731 50045333Email marion.flechtner-mors@uni-ulm.deContext: It is questioned whether the potato protein protease inhibitor II (PI2) reduces appetite and exerts effects on the satiety hormone cholecystokinin (CCK).Objective: To investigate PI2 impact on gastrointestinal hormones and appetite measures during weight reduction.Design: In a randomized, placebo-controlled trial over 20 weeks, fifty-two overweight/obese participants (BMI 25.2– 38.0 kg/m 2) received a protein-rich diet (30%) adjusted to 500 kcal below their individual daily needs. Subjects ingested a capsule containing either PI2 (150 mg) or placebo twice daily 1 hr before lunch and dinner. At week 0 and week 10 participants joined breakfast test meals to determine CCK, GLP-1, ghrelin, leptin, glucose and insulin concentrations in a time course experimental manner. Appetite sensations were measured on test meal days and in week 4, 9, 14 and 19 using visual analogue scales.Results: Weight loss at week 10 and 20 in the PI2 group was 4.3± 3.1 kg and 5.6± 4.1 kg, in the control group: 4.7± 4.0 kg and 6.8± 3.7 kg. A significant effect of PI2 on circulating CCK levels was observed at week 10. The other hormones were unaffected by PI2. At week 10, PI2 group subjects showed higher satiety and decreased desire to eat compared to placebo. During study duration, PI2 showed a significant impact on appetite ratings prior to lunch, one hour before dinner and just before dinner.Conclusion: PI2 increased circulating CCK plasma levels during the diet intervention. Likewise, PI2 modulated appetite sensation from week 4 to 20. The study demonstrated that the PI2 can modulate a key satiety signal.Keywords: dietary supplement, appetite, satiety modification, obesity
format article
author Flechtner-Mors M
Thoma U
Wittmann R
Boehm BO
Mors M
Steinacker JM
Schumann U
author_facet Flechtner-Mors M
Thoma U
Wittmann R
Boehm BO
Mors M
Steinacker JM
Schumann U
author_sort Flechtner-Mors M
title The Effect of Potato Protease Inhibitor II on Gastrointestinal Hormones and Satiety in Humans During Weight Reduction
title_short The Effect of Potato Protease Inhibitor II on Gastrointestinal Hormones and Satiety in Humans During Weight Reduction
title_full The Effect of Potato Protease Inhibitor II on Gastrointestinal Hormones and Satiety in Humans During Weight Reduction
title_fullStr The Effect of Potato Protease Inhibitor II on Gastrointestinal Hormones and Satiety in Humans During Weight Reduction
title_full_unstemmed The Effect of Potato Protease Inhibitor II on Gastrointestinal Hormones and Satiety in Humans During Weight Reduction
title_sort effect of potato protease inhibitor ii on gastrointestinal hormones and satiety in humans during weight reduction
publisher Dove Medical Press
publishDate 2020
url https://doaj.org/article/40a089c1b79d4c979d2fc93d97097cd4
work_keys_str_mv AT flechtnermorsm theeffectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction
AT thomau theeffectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction
AT wittmannr theeffectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction
AT boehmbo theeffectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction
AT morsm theeffectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction
AT steinackerjm theeffectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction
AT schumannu theeffectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction
AT flechtnermorsm effectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction
AT thomau effectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction
AT wittmannr effectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction
AT boehmbo effectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction
AT morsm effectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction
AT steinackerjm effectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction
AT schumannu effectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction
_version_ 1718399749595332608